International Medical Solution (IMS) has received US FDA Class II clearance for its cloud-based 3D cinematic rendering solution for medical images. IMS CloudVue provides healthcare clinicians and researchers the ability to view and share medical imaging in a highly secure cloud environment – from anywhere they can access an internet connection using any device. IMS' patented cinematic rendering will be included in the next release of IMS CloudVue.
IMS' architecture with Cinematic 3D provides a cost-effective and efficient solution for organizations that often require massive back-end servers to achieve a comparable result. While other solutions require 4 CPU cores per user for 3D imaging, IMS only needs 1 CPU core to support up to 30 users to view high-quality cinematic image renderings with the same performance.
"IMS CloudVue cinematic rendering is the best 3D imaging that I've ever used in a PACS-based environment. The quality of the 3D images and the smooth maneuverability of the 3D images is truly impressive. I see opportunities to improve clinical outcomes using this approach to imaging intracranial aneurysms and to help plan complex craniofacial surgeries. The fact that such 3D views are also available on the iPad and iPhone is an additional convenience," says Eric S. Bartlett, MPH MD, Assistant Professor, University of Toronto, Neuroradiology, Head and Neck Division.
CloudVue enables a clinician to access high-resolution images in the cloud on any device (desktop, laptop, smartphone, or tablet) with no cloud latency or application installs. A market leader, IMS' end-to-end solution provides business continuity and efficient health information exchange so clinicians can effectively review patient images and share their findings remotely.
"We believe that IMS is democratizing the market by providing a cost-effective solution for clinicians who wish to utilize mobile cinematic rendered images. By improving the realism of the images, it improves the perception of the anatomy by the clinician and enables more accurate diagnoses and better outcomes for patients," says Vittorio Accomazzi, CTO of IMS.Back To Top
Mobile Cinematic 3D Solution Received FDA Clearance. Appl Radiol.